AbCellera Biologics Inc. news
VANCOUVER, British Columbia, - AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present virtually at the 11th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17, 2022, at 12:40 p.m. Pacific Time.
A live audio webcast of the presentation may be accessed through a link that will be posted on AbCellera`s Investor Relations website
- Bebtelovimab (LY-CoV1404) neutralizes Omicron, including the subvariant BA.2, as demonstrated by pseudovirus and/or authentic virus data
- Previously reported data show that bebtelovimab has broad and potent neutralization of all other known circulating SARS-CoV-2 variants of concern
- Bebtelovimab binds to a rarely mutated region of the SARS-CoV-2 spike protein, suggesting the potential to retain effectiveness against emerging variants
Models of beb
VANCOUVER, British Columbia, – AbCellera (Nasdaq: ABCL) today announced Eli Lilly and Company (Lilly) has entered into a purchase agreement with the U.S. government to supply up to 600,000 doses, for at least $720 million, of investigational drug bebtelovimab (LY-CoV1404), the second antibody developed through AbCellera’s collaboration with Lilly. The U.S. government will accept the doses of bebtelovimab if it is granted an Emerge
VANCOUVER, British Columbia, – AbCellera (Nasdaq: ABCL) announced today that it will report full year 2021 financial results after market close on Thursday, February 24, 2022 and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.
The live webcast of the earnings conference will be available through a link that will be posted on
AbCellera and its collaborators released new preclinical data showing the pseudovirus neutralization status of its two monoclonal antibodies, bamlanivimab and bebtelovimab (also known as LY-CoV1404), against the Omicron variant.
The data confirmed that the investigational antibody bebtelovimab, which is currently in